Physician profile
Raynell Odom
NPI 1013071448
$954.52
in general payments reported to CMS, 2019-2025
15 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $111 · 2022: $409 · 2023: $275 · 2024: $34.82 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $435.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $434.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $194.38 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $157.03 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $143.34 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $121.35 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $98.31 | 2023 | |
| Supernus Pharmaceuticals, INC. | $47.31 | 2023-2024 | Qelbree, Qelbree |
| Lundbeck LLC | $37.49 | 2023 | Abilify Maintena |
| Janssen Pharmaceuticals, INC | $33.55 | 2023 | Invega Sustenna |
| Alkermes, INC. | $24.22 | 2022 | |
| Mylan Specialty L.P. | $23.45 | 2022 | |
| Amgen INC. | $16.64 | 2023 | Repatha, Otezla |
| Indivior INC. | $15.25 | 2024 | Perseris |
| Uswm, LLC | $15.22 | 2021 | |
| Sunovion Pharmaceuticals INC. | $14.34 | 2022 | |
| Lilly USA, LLC | $12.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raynell Odom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.